JSPR Wutah bathi EPS kuartalan Jasper Therapeutics, Inc.

Simbol resmi perusahaan jaspertherapeutics.com (JSPR)

Exclusive patents for transplant preparation create a significant barrier to entry for competitors. The quarterly EPS growth history displayed on GURU.Markets shows that this metric stands at 93.70. Future revenues are based on the commercialization of antibodies for bone marrow cleansing, although the model currently relies on venture capital due to a lack of pricing power during the testing phase for Jasper Therapeutics (JSPR).

Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan Jasper Therapeutics, Inc. (JSPR): kanggo periode 04.07.2022 - 16.11.2026

jaspertherapeutics.com (JSPR) - rincian metrik lan laporan keuangan

- rega saham lan prakiraan rega para ahli:
Analisis fundamental perusahaan:Jasper Therapeutics Inc - JSPR
Produk dadi Jasper Therapeutics

Diversification of clinical developments in oncology and immunology minimizes risks for Jasper Therapeutics (JSPR), which is reflected in the quarterly growth dynamics of earnings per share. This indicator measures the percentage change in net income per common share relative to the previous period, allowing investors to assess the pace of business scaling and adjust the fair value calculation of the asset.